Sociodemographic differences in prevalence of diagnosed coronary heart disease in New Zealand estimated from linked national health records

Section of Epidemiology and Biostatistics, School of Population Health, Tamaki Campus, University of Auckland, Private Bag 92019, Auckland, New Zealand.
The New Zealand medical journal 05/2011; 124(1334):21-34.
Source: PubMed


To estimate sociodemographic differences in the prevalence of coronary heart disease (CHD) in New Zealand from linked health records.
We combined records of hospital treatment for CHD, dispensing of selected anti-anginal drugs and mortality to estimate the national point prevalence of coronary heart disease in New Zealand in December 2008. Stratified estimates are presented by gender; age; Māori, Pacific, Indian and 'Other' (mainly New Zealand European) ethnic groups; and socioeconomic status.
Among a "health contact" population of adults (greater than and equal to 15 years), about one in twenty (6.5% of men and 4.1% of women) had indicators of a past diagnosis or treatment for CHD or both. Substantial differences in prevalence occurred by gender, ethnic group and socioeconomic status. For example, among New Zealanders aged 35 to 74 years, Indian men had the highest age-adjusted prevalence (7.78%; 95%CI 7.43 to 8.15), almost double the prevalence of 'Other' males. Among women, Māori had the highest adjusted prevalence (4.03%; 95% CI 3.89 to 4.17), just over twice that of 'Others.'
Major sociodemographic disparities in the national burden of CHD persist. Our results are similar to previous studies of ethnic disparities in CHD incidence, but also confirm concerns about the emerging CHD burden among South Asians. Indian males have the highest CHD prevalence of any gender-specific ethnic group. Of equal concern, Māori women have a similar prevalence to European males.

Download full-text


Available from: Suneela Mehta,
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the co-prevalence of gout, diabetes and cardiovascular disease (CVD) in the entire Aotearoa New Zealand adult population to inform clinical practice. Algorithms based on hospital admissions, outpatient visits, drug dispensing, laboratory test data and mortality for the Aotearoa New Zealand Health Tracker (ANZHT) population aged =20 years (n = 3,036,093) were used to estimate the prevalence of those identified with gout, diabetes and CVD in 2009. The crude prevalence in the adult ANZHT population of gout was 3.9%, of diabetes was 6.6%, and of CVD was 5.4%. For those identified with gout, 25.6% had diabetes and 22.7% had CVD. Both diabetes and CVD were more prevalent in those identified with gout, compared with those without gout (age-standardised rate (ASR) ratio 3.5 for diabetes and 2.7 for CVD, p for both <0.001). By applying algorithms based on hospital coding, community drug dispensing and laboratory test data sets, we have demonstrated a high co-prevalence of gout, diabetes and CVD in the adult population of Aotearoa New Zealand. Health service presentation with gout can be an important opportunity to assess risk and manage co-morbid disease. Prevention and management strategies are reinforcing for these metabolic conditions.
    The New Zealand medical journal 01/2012; 126(1368):53-64.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: With studies reporting both positive and negative associations, the influence of serum urate on incident cardiovascular disease (CVD) is uncertain. We sought to determine whether serum urate is causally associated with incident CVD. Methods: Participants were aged 30-80 years and were screened for CVD risk in primary care between 2006 and 2009. Participants had blood pressure, lipids, age and ethnic group recorded at assessment, with record linkage providing drug dispensing, hospital diagnoses and laboratory test results. Outcomes were derived from hospital diagnoses and mortality records until December 2009. Cox models were used to assess the influence of exposures on outcomes. Results: A total of 78 707 people, free of CVD, were enrolled, and 1328 CVD events occurred during follow-up. Serum urate was recorded before baseline assessment in 43% (34 008/78 707) of participants. After adjustment for confounding factors, a 2 s.d. difference in serum urate (0.45 vs 0.27 mmol/l) was associated with a hazard ratio (HR) of 1.56 (95% CI 1.32, 1.84). This was more than double that of the equivalent distributional change in high-density lipoprotein cholesterol (adjusted HR 1.22) and one-third greater than that for HbA1c (adjusted HR 1.41). Conclusion: Serum urate is likely to be causally associated with CVD. This supports public health action to reduce urate levels in populations with significant burdens of the disease.
    Rheumatology (Oxford, England) 10/2012; 52(1). DOI:10.1093/rheumatology/kes269 · 4.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Disparities for Maori exist in New Zealand for cardiovascular risk factors, events and access to revascularisation. We compared characteristics and outcomes of coronary artery bypass grafting (CABG) between Maori and Europeans in New Zealand. Patients undergoing isolated CABG at Auckland City Hospital from July 2010-June 2012 were retrospectively analysed. Of 818 patients, 82 were Maori and 444 were Europeans. Maori were younger (60.0 vs 67.9 years, p<0.001), had higher NZ deprivation index (8.5 vs 5.0, p<0.001), body mass index (32.6 vs 28.8 kg/m2, p<0.001), higher prevalence of heart failure (11.0% vs 2.3%, p<0.001), diabetes (43.9% vs 24.1%, p<0.001), smoking (39.0% vs 13.1%, p<0.001), dialysis (4.9% vs 0.9%, p=0.023), lower ejection fraction (p=0.001), lower additive EuroSCORE 1 (4.1 vs 4.8, p=0.041) and longer cardiopulmonary bypass time (100 vs 89 minutes p<0.001). Maori ethnicity was independently associated with 30-day mortality, odds ratio (OR) 6.35, 95% confidence interval 1.01-39.9, p=0.046; and surgical morbidity OR 2.05, 1.04-4.04, p=0.040. Maori had a trend for higher mortality at 1.4 plus or minus 0.6 years (hazards ratio 2.91, 0.92-9.20, p=0.069), 1-year mortality 6.3% vs 1.5%. Despite being younger, Maori undergoing CABG had more comorbidities and socioeconomic deprivation. Maori had higher mortality and complication rates. Maori should have earlier access to CABG.
    The New Zealand medical journal 09/2013; 126(1379):12-22.
Show more